Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr Makrigiorgos graduated from the University of Athens, Greece in 1981 (BSc) and from the University of Leeds, UK in 1984 (Ph.D). Following a postdoctoral fellowship in radiation biology at Harvard Medical School he joined the faculty of the Joint Center for Radiation Therapy, Harvard Medical School. He is currently the Director of the Medical Physics and Biophysics Division of the joint department of radiation therapy at Dana Farber Cancer Institute and Brigham and Women’s Hospital and a Professor at Harvard Medical School. He is as ABR-certified radiation oncology physicist, an NIH-funded principal investigator of a DNA technology laboratory and director of a radiation pre-clinical facility. He is on the Editorial Board of Clinical Chemistry and has published over 150 articles, reviews and book chapters.
We are developing technologies for molecular profiling of human tumors. In particular, we have devised technologies for detecting low-level DNA mutations, micro-satellite instability and methylation in clinical samples. We are using these new technologies to improve detection of cancer DNA biomarkers in human blood (‘liquid biopsies’), for the purpose of early detection of cancer, and for monitoring the progress of radio/chemotherapy or for detection of minimal residual disease. Ongoing clinical studies are evaluating these biomarkers in radiation oncology and medical oncology patients.
Brigham and Women's Hospital75 Francis StreetBoston MA, 02215Get Directions